The latest price target for Sanara MedTech (NASDAQ:SMTI) was reported by Cantor Fitzgerald on May 15, 2024. The analyst firm set a price target for $44.00 expecting SMTI to rise to within 12 months (a possible 18.03% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Sanara MedTech (NASDAQ:SMTI) was provided by Cantor Fitzgerald, and Sanara MedTech reiterated their overweight rating.

There is no last upgrade for Sanara MedTech

There is no last downgrade for Sanara MedTech.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sanara MedTech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sanara MedTech was filed on May 15, 2024 so you should expect the next rating to be made available sometime around May 15, 2025.

While ratings are subjective and will change, the latest Sanara MedTech (SMTI) rating was a reiterated with a price target of $44.00 to $44.00. The current price Sanara MedTech (SMTI) is trading at is $37.28, which is out of the analyst’s predicted range.